Baxalta and Momenta's partnership would be the seventh company or pairing of companies in the late stages of attempting to create a biosimilar of Humira, which generates 60 percent of AbbVie's annual revenue, said Damien Conover, a Morningstar analyst. Even more companies are seeking to develop one but aren't as far along.